Rigel Pharmaceuticals Inc
RIGL35.110USD
+0.890+2.60%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
629.77MMarktkapitalisierung
6.44KGV TTM
mehr Informationen über Rigel Pharmaceuticals Inc Unternehmen
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Unternehmensinformationen
BörsenkürzelRIGL
Name des UnternehmensRigel Pharmaceuticals Inc
IPO-datumNov 29, 2000
CEOMr. Raul R. Rodriguez
Anzahl der mitarbeiter162
WertpapierartOrdinary Share
GeschäftsjahresendeNov 29
Addresse- -
Stadt- -
BörseNASDAQ Global Select Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelRIGL
IPO-datumNov 29, 2000
CEOMr. Raul R. Rodriguez
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
8.92%
Morgan Stanley & Co. LLC
8.25%
BlackRock Institutional Trust Company, N.A.
7.85%
The Vanguard Group, Inc.
5.87%
Soleus Capital Management, L.P.
3.67%
Andere
65.45%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
8.92%
Morgan Stanley & Co. LLC
8.25%
BlackRock Institutional Trust Company, N.A.
7.85%
The Vanguard Group, Inc.
5.87%
Soleus Capital Management, L.P.
3.67%
Andere
65.45%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.38%
Investment Advisor/Hedge Fund
23.07%
Hedge Fund
16.28%
Research Firm
10.35%
Individual Investor
2.65%
Pension Fund
0.76%
Bank and Trust
0.14%
Insurance Company
0.04%
Andere
17.33%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
290
14.23M
79.32%
-22.43K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
2023Q1
359
12.15M
69.98%
-5.32M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
1.52M
8.48%
+364.00K
+31.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.48M
8.28%
-54.14K
-3.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.47M
8.23%
-33.13K
-2.20%
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
5.75%
+15.14K
+1.49%
Mar 31, 2025
Soleus Capital Management, L.P.
1.13M
6.33%
--
--
Mar 31, 2025
Acadian Asset Management LLC
565.04K
3.16%
+188.68K
+50.13%
Mar 31, 2025
State Street Global Advisors (US)
637.03K
3.56%
+256.52K
+67.41%
Mar 31, 2025
Capitolis Liquid Global Markets LLC
693.10K
3.88%
+693.10K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
411.17K
2.3%
+9.12K
+2.27%
Mar 31, 2025
Marshall Wace LLP
211.75K
1.18%
+211.75K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
Invesco Nasdaq Biotechnology ETF
0.07%
Franklin US Small Cap Multifactor Index ETF
0.05%
Innovator US Small Cap Managed Floor ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis Responsible US Equity ETF
0.01%
Pacer US Small Cap Cash Cows ETF
0%
Mehr Anzeigen
Invesco Nasdaq Biotechnology ETF
Anteil0.07%
Franklin US Small Cap Multifactor Index ETF
Anteil0.05%
Innovator US Small Cap Managed Floor ETF
Anteil0.04%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.04%
ProShares Hedge Replication ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Avantis Responsible US Equity ETF
Anteil0.01%
Pacer US Small Cap Cash Cows ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Datum
Art
Verhältnis
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
